Hill Welcomes Addition of Selinexor to DLBCL Armamentarium
The recent approval of selinexor (Xpovio) provides a novel treatment for patients with diffuse large B-cell lymphoma who have exhausted available options.
The recent approval of selinexor (Xpovio) provides a novel treatment for patients with diffuse large B-cell lymphoma who have exhausted available options.
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS…
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Acalabrutinib combination therapy elicits statistically significant improvement in progression-free survival for treatment-naive mantle cell lymphoma.
Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma.